In animal models, it has been demonstrated that acute GVHD is caused by immunocompetent donor T-lymphocytes which recognize histocompatibility antigens of the recipient. Pilot studies have been carried out to evaluate the effects of in vitro depletion of T-lymphocytes from donor marrow in patients receiving HLA-identical marrow grafts for treatment of hematologic malignancies. Although initial engraftment was not affected, the incidence of subsequent graft failure was strikingly increased. These findings suggested that certain T-cells in the donor marrow serve a beneficial function by eliminating host cells that can cause graft failure. In addition, despite at least 2-3 log depletion of T-cells, half of the patients who received no posttransplant immunosuppression developed grade II acute GVHD. Finally, two patients developed a fatal Epstein-Barr virus (EBV)-related lymphoproliferative syndrome after receiving T- cell-depleted allogeneic marrow. The proposed studies are therefore aimed at the problems of graft failure, GVHD and immune reconstitution in patients receiving T-cell depleted allogeneic marrow transplants. Clinical protocols will explore whether cells that facilitate engraftment can be distinguished from cells that cause GVHD and whether additional pretransplant immunosuppression can facilitate durable engraftment by ablating host cells that can cause graft failure. If GVHD occurs, studies will be carried out to determine whether this reflects inadequate T-cell depletion or immune dysregulation of host cells. Finally, the effects of T-cell depletion on humoral an cellular responses to EBV will be assessed. If durable engraftment and immune reconstitution were assured, depletion of T-cells from donor marrow could become a highly effective and safe method for preventing acute GVHD after allogeneic marrow transplantation. More importantly, it might become possible to decrease the morbidity associated with transplantation of marrow from HLA- non-identical donors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-15
Application #
3811904
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764
Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Lee, Stephanie J; Onstad, Lynn; Chow, Eric J et al. (2018) Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103:1535-1541
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849

Showing the most recent 10 out of 1845 publications